Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seventeen ratings firms that are presently covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $55.06.

A number of analysts have commented on the company. Truist Financial restated a "buy" rating and issued a $53.00 price target (down previously from $54.00) on shares of Kymera Therapeutics in a research report on Friday, November 1st. Stephens restated an "overweight" rating and set a $60.00 target price on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. Guggenheim increased their price target on Kymera Therapeutics from $45.00 to $52.00 and gave the stock a "buy" rating in a research note on Friday, November 1st. BMO Capital Markets began coverage on Kymera Therapeutics in a research report on Friday, December 6th. They issued a "market perform" rating and a $55.00 price objective on the stock. Finally, Leerink Partners reiterated an "outperform" rating and set a $60.00 target price on shares of Kymera Therapeutics in a research report on Friday, December 27th.

Kymera Therapeutics Trading Down 0.6 %

KYMR stock traded down $0.23 on Monday, hitting $37.42. The company had a trading volume of 427,904 shares, compared to its average volume of 490,905. Kymera Therapeutics has a 12-month low of $29.24 and a 12-month high of $53.27. The stock has a market cap of $2.42 billion, a price-to-earnings ratio of -15.99 and a beta of 2.18. The stock's 50-day simple moving average is $39.97 and its 200 day simple moving average is $44.09.

Insider Activity

In related news, insider Ellen Chiniara sold 3,129 shares of the company's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $41.75, for a total transaction of $130,635.75. Following the transaction, the insider now directly owns 54,826 shares in the company, valued at approximately $2,288,985.50. This represents a 5.40 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 15.82% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Wellington Management Group LLP lifted its stake in shares of Kymera Therapeutics by 14.9% during the 4th quarter. Wellington Management Group LLP now owns 5,307,326 shares of the company's stock worth $213,514,000 after acquiring an additional 688,967 shares during the last quarter. Avoro Capital Advisors LLC lifted its position in shares of Kymera Therapeutics by 14.4% during the fourth quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company's stock worth $207,184,000 after purchasing an additional 650,000 shares during the last quarter. Deerfield Management Company L.P. Series C purchased a new stake in shares of Kymera Therapeutics during the fourth quarter valued at $23,856,000. Boxer Capital Management LLC bought a new position in shares of Kymera Therapeutics in the fourth quarter worth about $17,098,000. Finally, Jennison Associates LLC lifted its holdings in Kymera Therapeutics by 85.8% during the 3rd quarter. Jennison Associates LLC now owns 797,681 shares of the company's stock valued at $37,754,000 after buying an additional 368,394 shares in the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.